OniX provides an alternative for research partnering and funding: Too many ideas, not enough funding
Was your grant application unfunded, or the review was cancelled/delayed? Register and submit your non-confidential abstract to OniX. It is free.
The 2008 global financial crisis (GFC) was a severe worldwide crisis. One that many organizations still are recovering from. Now, the world is going through the COVID-19 Pandemic. The impact of COVID-19’s shelter-in-place orders throughout the world has had a negative impact on the fundraising activities of many private foundations that support vital biomedical research.
Private Foundations fund over $4B dollars of biomedical research primarily to academic centers every year. As a consequence of the pandemic, the budget decreases at these foundations are already being felt. The American Cancer Society (ACS) in the United States and Cancer Research UK (CRUK) in England have cancelled new funding through the end of 2020 and their budget for 2021 is projected to decrease 10-20%. ACS and CRUK are two of the largest private funders of biomedical research, which paints a very frightening picture for smaller foundations’ financial challenges now and in the years to come.
OniX—the Online Ideas Exchange Hub—provides an opportunity for partnering and funding for unfunded applications originally submitted to government funding agencies, private foundations and intramural funding opportunities. OniX matches unfunded applications from universities, startups and biotech companies with research priority areas of non-government organizations, i.e, pharmaceutical companies, venture capital and private equity funds, family offices, private biomedical foundations, and other private funds.
Each year, hundreds of innovative, research applications are left unfunded. Currently, global government funding agencies on average fund <15% of the research applications they receive, and the pandemic might be affecting these pay-lines. The Canadian Institutes of Health Research (CIHR) has cancelled its next funding round, though others in the UK, Europe, USA and Australia, for now have kept funding pay-lines for 2020.
OniX is a partnering and funding platform and a multi-stakeholder collaboration hub to advance research discovery and drug development. OniX accepts all types of research, from early discovery and basic research through translational and clinical research. OniX also receives abstracts from other areas of research, including Agriculture, Energy, Space, Transportation, Climate Change, Food and Nutrition, Farming, Fisheries, Social Sciences, Public Health, Artificial Intelligence, Software/Hardware, and others.
As funding agencies make difficult decisions from the result of the negative financial impact of the pandemic, it is imperative that we, as a society, continue to find ways to advance research discoveries and development. The COVID-19 pandemic caught the world inadequately prepared and exposed the consequences of long-term failure to sufficiently invest in scientific research. The pandemic has exposed the necessity to invest into research, education and training, technology transfer and entrepreneurship, manufacturing, and the broader innovation ecosystem across the world. OniX is a public - private partnership that advances partnership, provides funding through its
members and creates a knowledge ecosystem to advance critical R&D to bring medicine and solutions to market to benefit communities around the world.
Universities can reach out to partner with OniX to share their not confidential abstracts of unfunded research applications, technology transfer assets and intramural projects. Incubators, Accelerators and Research Parks can reach out to provide their tenants the opportunity to share their non-confidential technology summaries with OniX. Industry, including pharmaceutical, agriculture, energy, AI, and other companies, and venture capital and private funds can reach out to become members. Foundations can become members of OniX. Anyone can submit non-confidential abstracts to OniX at no cost.